Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09

Summary

This will be a randomized, double-blind, placebo-controlled, rising-dose study of single IV doses of AR09 in healthy subjects. Each infusion will occur over 10 minutes.

Timeline

Start

2013-12

Primary completion

2014-04

Completion

2014-04

Outcome

Outcome not reported

Stopped: “Study stopping criteria was met”

Drugs

Indications

No indication recorded.